Comparative Pharmacology
Head-to-head clinical analysis: DUONEB versus TOLTERODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUONEB versus TOLTERODINE.
DUONEB vs TOLTERODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUONEB is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist). Ipratropium inhibits muscarinic acetylcholine receptors in bronchial smooth muscle, reducing vagal tone and bronchodilation. Albuterol stimulates beta-2 adrenergic receptors, leading to relaxation of bronchial smooth muscle.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with selectivity for the M3 receptor subtype involved in detrusor muscle contraction, reducing bladder smooth muscle contractility and increasing bladder capacity.
1-2 vials (2.5 mg ipratropium bromide/2.5 mg albuterol sulfate per 3 mL vial) via nebulization every 6 hours as needed; maximum 6 vials per day.
2 mg PO twice daily; may reduce to 1 mg twice daily if tolerated.
None Documented
None Documented
Clinical Note
moderateTolterodine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Clotrimazole
Ipratropium: terminal half-life ~2 hours (range 1.5-4 hours). Albuterol: terminal half-life 3.8-6 hours (mean ~4.6 hours). Clinical context: Both contribute to bronchodilation lasting 4-6 hours.
Terminal elimination half-life is 2-4 hours in extensive CYP2D6 metabolizers; increased to 4-10 hours in poor metabolizers or with CYP3A4 inhibitors.
DuoNeb (ipratropium bromide/albuterol sulfate) is a fixed-dose combination. Ipratropium: 90% excreted unchanged in feces (biliary), <10% renal. Albuterol: 60-70% renal as unchanged drug and metabolites (sulfate conjugate), 30-40% fecal.
Primarily hepatic metabolism via CYP2D6 and CYP3A4; renal excretion accounts for <5% of unchanged drug; ~80% excreted in urine as metabolites, ~20% in feces.
Category C
Category A/B
Anticholinergic/Beta2-Agonist Combination
Anticholinergic
"The metabolism of Clotrimazole can be decreased when combined with Tolterodine."